BNTX
$94.86
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase...
Recent News
BioNTech Stock Is a Bargain. Why Its Recent Selloff Is a Buying Opportunity.
The company’s cash and securities nearly equal its market value, meaning investors aren’t paying much for the Covid franchise and a pipeline focused on cancer treatments.
Man's dog was riddled with tumors and dying. He used ChatGPT to design a custom cancer vaccine, stunning researchers
With no biology degree and just $3,000, he designed a personalized mRNA vaccine in a world first. Moderna and Merck are spending billions to bring the same technology to human patients.
Is BioNTech (BNTX) Starting To Look Attractive After Recent Share Price Weakness
If you are wondering whether BioNTech is starting to look like value after the Covid vaccine boom faded, or if the current price still feels rich, this article walks through what the numbers actually say about the stock. BioNTech shares last closed at US$90.84, after a 12.5% decline over 7 days, a 17.7% decline over 30 days, a 6.1% decline year to date, and a 9.4% decline over 1 year, with a 30.1% decline over 3 years and a 14.0% decline over 5 years. Recent coverage around BioNTech has...
European Equities Traded in the US as American Depositary Receipts Edge Lower in Wednesday Trading
European equities traded in the US as American depositary receipts edged lower late Wednesday mornin
US Stock Market Today: S&P 500 Futures Edge Lower As Inflation Jitters Linger
The Morning Bull - US Market Morning Update Wednesday, Mar, 11 2026 E mini S&P 500 futures are slightly lower this morning as investors weigh a mix of housing, jobs and bond market signals. Existing home sales sit at an annual pace of 4.09 million, with the typical home priced at US$398,000, which matters for anyone thinking about moving or tapping home equity. Private sector job gains of about 15,500 a week show the job market is still adding positions, supporting paychecks and spending...